Harbin Pharmaceutical Group (600664.SH): Cefuroxime Sodium for Injection passes generic drug consistency evaluation.

Harbin Pharmaceutical Group (600664.SH) announced recently that its affiliated enterprise, Harbin Pharmaceutical Group Pharmaceutical General Factory (referred to as "Harbin Pharmaceutical General Factory"), has received the "Drug Supplementary Application Approval Notice" for injection cefradine sodium from the National Medical Products Administration, with reference number 2025B00252. This product has passed the evaluation for generic drug quality and efficacy consistency. In order to reduce the emergence of drug-resistant bacteria and maintain the effectiveness of injection cefradine sodium and other antibiotics, this product is only used for the treatment or prevention of infections confirmed or strongly suspected to be caused by sensitive bacteria. Injection cefradine sodium is suitable for the treatment of severe infections caused by sensitive bacteria, including lower respiratory tract infections, urinary tract infections, intra-abdominal infections, gynecological infections, sepsis, bone and joint infections, and skin and soft tissue infections. Injection cefradine sodium can also be used for infection prevention before clean gastrointestinal surgeries, as well as before vaginal hysterectomy, abdominal hysterectomy, or cesarean section surgeries.